Global Non-alcoholic Steatohepatitis Biomarkers Market Forecast, 2022-2028

Description

List of Tables

Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size, Share & Trends Analysis Report by Biomarker Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others), and by End-Users (Hospitals, Diagnostic Laboratories, Academic Research Institute, and Pharmaceutical Companies/CRO) Forecast Period (2022-2028)

The global NASH biomarkers market is anticipated to grow at a substantial CAGR of 28.6% during the forecast period. NASH is a type of NAFLD (Non-alcoholic fatty liver disease) or a condition in which lots of fat is accumulated in the liver. There are two types of NAFLD, which include NAFL (nonalcoholic fatty liver) and NASH (nonalcoholic steatohepatitis). Inflammation and damage to the liver occur in NASH, which can cause fibrosis of the liver. It can also lead to cirrhosis, in which the liver is permanently scarred and damaged. The primary factor supporting the market growth includes the increasing obesity across the globe. According to the data published by Our World in Data Organization, in 2021, around 13% of the global population is suffering from the issue of obesity. NASH tends to develop in people who are overweight or obese and have diabetes, high cholesterol, or high triglycerides. However, some people have NASH even if they do not have any risk factors.

The global NASH biomarkers market is sub-segmented based on biomarker type and end-users. Based on biomarker type, the market is sub-segmented into Serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others. Based on end-users, the market is sub-segmented into hospitals, diagnostic laboratories, academic research institutes, and pharmaceutical companies/CROs. Among these, the serum biomarkers segment is anticipated to grow at are markable pace, as it is a non-invasive treatment, and also has the potential in diagnosing NAFLD and NASH. People prefer non-invasive treatment the invasive treatment. Hence, these factors contribute to the growth of the global NASH biomarkers market.

Geographically the global NASH biomarkers market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold a prominent share in the market and is expected to hold its position in the coming years. The growth is majorly attributed due to the increasing number of diabetic patients in the region and other innovations and initiatives. According to the American Diabetes Association, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes and around 1.9 million Americans have type 1 diabetes, including about 244,000 children and adolescents. Diabetes was the seventh leading cause of death in the United States in 2019 based on the 87,647 death certificates in which diabetes was listed as the underlying cause of death.

The major companies serving the global NASH biomarkers market are Allergan PLC, Bristol-Myers Squibb Co., Gilead Sciences, Inc., Siemens Healthcare Medical Solutions Ltd., and Thermo Fisher Scientific, Inc., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in 2020, Novo Nordisk acquired Emisphere Technologies Inc. for $1.35 billion a proprietor technology drug delivery company, such as Eligen SNAC technology, which allows for oral therapeutic formulations.

Research Methodology

The market study of the global NASH biomarkers market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Research and Analysis by Biomarker Type.

Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Research and Analysis by End-User.

The Report Covers

Comprehensive research methodology of the global on-alcoholic steatohepatitis(NASH)biomarkers market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global non-alcoholic steatohepatitis (NASH)biomarkers market.

Insights about market determinants that are stimulating the global non-alcoholic steatohepatitis (NASH)biomarkers market.

Detailed and extensive market segments with the regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Product Code: OMR2019504

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the GlobalNASH BiomarkersMarket
Recovery Scenario of GlobalNASH BiomarkersMarket
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. ByRegion

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

4.1. GlobalNASH BiomarkersMarket by Biomarker Type
- 4.1.1. Serum Biomarkers
- 4.1.2. Hepatic Fibrosis Biomarkers
- 4.1.3. Apoptosis Biomarkers
- 4.1.4. Oxidative Stress Biomarkers
- 4.1.5. Others (Carbon Isotope Markers and miRNA Biomarkers)
4.2. Global NASH BiomarkersMarket by End-Users
- 4.2.1. Hospitals
- 4.2.2. Diagnostic Laboratories
- 4.2.3. Academic Research Institute
- 4.2.4. Pharmaceutical Companies/CRO

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Allergan PLC
6.2. ALPCO
6.3. Antaros Medical AB
6.4. BioPredictive S.A.S
6.5. Boehringer Ingelheim International GmbH
6.6. Bristol-Myers Squibb Co.
6.7. Covance Inc.
6.8. Enterome SA
6.9. GENFIT SA
6.10. Gilead Sciences, Inc.
6.11. Laboratory Corporation of America Holdings
6.12. NGM Biopharmaceuticals, Inc.
6.13. Nordic Bioscience
6.14. OWL Metabolomics
6.15. Perspectum Diagnostics Ltd
6.16. Prometheus Laboratories Inc.
6.17. ProSciento
6.18. Quest Diagnostics Inc.
6.19. Siemens Healthcare Medical Solutions Ltd.
6.20. Thermo Fisher Scientific, Inc.
6.21. XeptagenSpA